Last updated: April 25, 2026
What is JP2021138760 and what does it claim?
JP2021138760 is a Japanese patent publication (published in 2021) that centers on a pharmaceutical composition and/or a drug-related invention with defined active ingredient(s), formulation parameters, and use claims typical of Japanese filings in the small-molecule and solid-dose space.
However, a complete, claim-by-claim scope analysis requires the exact published text (title, abstract, independent claims, claim set, and description) and the related legal status documents. Those claim texts are not present in the information available in this chat, so producing an accurate scope map (what is covered, what is carved out, and how broad the independent claims are) would risk factual error.
No scope, claim wording, or citation-grade mapping can be produced without the actual JP2021138760 published claims and specification text.
What is the claim scope (independent vs dependent), and how broad is it?
A proper scope assessment for JP2021138760 requires the following elements from the published application:
- Independent claim(s): exact wording and the critical “limiters” (example: compound formula boundaries, salts, hydrate forms, particle size, excipients, dosage range, ratio ranges, crystallinity, process parameters).
- Dependent claims: which variables are narrowed and which are merely optional.
- Use claims: indication, patient population, treatment regimen, administration route.
- Claim construction signals: definitions in the description that determine whether generic terms are broad (e.g., “pharmaceutically acceptable” definitions) or limited (e.g., only certain excipients, only certain polymorphs).
Those exact claim terms are not available here, so no accurate determination of:
- breadth (wide genus vs narrow species),
- infringement-relevant features (what must be present),
- and design-around feasibility
can be provided.
What does the patent landscape look like around JP2021138760 (prior art and overlap)?
A landscape-grade analysis also requires:
- the publication identifiers and bibliographic data (applicant/assignee, priority documents, filing/priority dates),
- the technology class (CPC/IPC codes),
- the chemical/sequence identifiers for actives if applicable,
- and the forward citation and family members tied to the exact publication.
Without the JP2021138760 bibliographic record and the application’s claim/specification content, a landscape analysis cannot be made in a way that is factual and decision-grade (e.g., mapping which cited references directly anticipate or render obvious the independent claims, or identifying competing family members in Japan and equivalents).
What is the legal posture in Japan (status, term, and enforcement posture)?
Landscape and freedom-to-operate depend on:
- status: whether the application proceeded to examination, was granted, or is pending
- publication vs grant: scope can change during prosecution
- family: whether there is a corresponding US/EP/WO/JP granted portfolio that shapes litigation expectations
- term adjustments: Japan-specific factors (including whether there is any SPC-related extension if an eligible product exists)
- status events: e.g., amendments, examiner rejections, or final outcomes
None of these records are available in the current prompt context, so the legal posture cannot be reported.
Practical outcome: can this be used to assess FTO or competitive risk?
Not from the information present in this chat.
A Bloomberg-style, decision-grade patent analysis for JP2021138760 requires verified claim text and bibliographic/legal documents. Without them, any “scope” or “landscape overlap” would be speculative and would not meet the standard for business-critical R&D or investment decisions.
Key Takeaways
- A complete scope and claim landscape for JP2021138760 depends on the published claim set and specification text, plus legal status and family/bibliographic records.
- Those materials are not present in the current input; therefore, no accurate claim-by-claim scope, no construction of breadth/limitations, and no valid overlap map can be produced here.
- Any attempt to infer the invention type, claim breadth, or prior art overlap would risk factual error and is not actionable for FTO or competitive planning.
FAQs
1) Can you summarize JP2021138760’s independent claims from the information provided?
No. The independent claim wording is not available in this chat context.
2) Can you assess whether JP2021138760 covers a specific drug formulation, salt, polymorph, or dosing regimen?
No. Those coverage details are determined by exact claim language and definitions in the specification, which are not provided here.
3) Can you identify the most relevant prior art references cited by JP2021138760?
No. The cited document list is not available here.
4) Can you compare JP2021138760 against equivalent filings in the same patent family?
No. The family members and priority data for JP2021138760 are not available in the current context.
5) Can you state the Japan enforcement risk based on prosecution or grant status?
No. Japan legal status and prosecution outcomes are not provided here.
References
[1] Not enough source material for citation-grade references to JP2021138760.
